Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)

To join this study, you would need to have non-small cell lung cancer that can be removed by surgery, specifically stages II, IIIA, or a certain type of IIIB cancer. It's important that your cancer hasn't been treated before. The medical team will also need a sample of your tumour tissue to check specific markers. You should also be generally well and able to carry out most normal daily activities, as assessed by your doctor.

There are some reasons why you might not be able to join. For example, if your lung cancer is in a very specific location, or if it's a rare type of lung cancer. You also wouldn't be able to join if you have a history of serious lung inflammation that needed strong medication like steroids, or certain serious infections. If you've had an organ transplant or have an active autoimmune disease requiring ongoing treatment, you also wouldn't be able to participate. You also can't have a known severe allergy to pembrolizumab or any of the chemotherapy drugs used in the study.

If you are a woman who could become pregnant, or a man, you must agree to use effective birth control throughout the study and for some time after the last treatment. Women also cannot be pregnant or breastfeeding. These measures are in place because the study drugs could potentially harm an unborn baby.

If you decide to take part in this study, you will first receive treatment before your surgery. This will involve a combination of either pembrolizumab or a placebo, given alongside standard chemotherapy. After that phase, you will have your surgery. Following surgery, you will continue to receive either pembrolizumab or a placebo. The chemotherapy drugs used are cisplatin, gemcitabine, or pemetrexed – your doctor will discuss which is right for you.

Throughout the study, you will have regular visits to the hospital for doctors' appointments, blood tests, scans, and to receive your medication. These visits will help the medical team monitor your health, check how well the treatment is working, and look for any side effects. After your treatment phases are complete, you will have long-term follow-up appointments to track your health and how your cancer is doing over time. The total duration of the treatment and follow-up will be explained by the study team, but it's important to remember that such studies often involve several years of monitoring.